Cargando…
Combination phosphodiesterase type 4 inhibitor and phosphodiesterase type 5 inhibitor treatment reduces non-voiding contraction in a rat model of overactive bladder
INTRODUCTION: Current treatments for overactive bladder (OAB) are often discontinued due to side effects or lack of efficacy. The goal of this study was to determine if combining a phosphodiesterase type 4 inhibitor (PDE4i); with a type 5 inhibitor (PDE5i); would have a beneficial effect on OAB symp...
Autores principales: | Balog, Brian M., Tangada, Abhilasha, Sheth, Pooja, Song, Qi-Xiang, Couri, Bruna M., Porras, Leah L., Deng, Gary G., Damaser, Margot S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713339/ https://www.ncbi.nlm.nih.gov/pubmed/31461445 http://dx.doi.org/10.1371/journal.pone.0220788 |
Ejemplares similares
-
Effect of phosphodiesterase inhibitors in the bladder
por: Chughtai, Bilal, et al.
Publicado: (2015) -
Overactive Bladder Syndrome and the Potential Role of Prostaglandins and Phosphodiesterases: An Introduction
por: Rahnama'i, Mohammad Sajjad, et al.
Publicado: (2013) -
Sildenafil, a phosphodiesterase type 5 inhibitor, augments sphincter bursting and bladder afferent activity to enhance storage function and voiding efficiency in mice
por: Ito, Hiroki, et al.
Publicado: (2019) -
AB030. Evolution of phosphodiesterase type 5 inhibitors
por: Moon, Du Geon
Publicado: (2016) -
COVID-19 and Phosphodiesterase Enzyme Type 5 Inhibitors
por: Al-Kuraishy, Hayder M., et al.
Publicado: (2020)